---
schema_version: "secwatch.filing_event.v1"
accession: "0001664710-24-000067"
form_type: "8-K"
ticker: "KROS"
cik: "0001664710"
company_name: "Keros Therapeutics, Inc."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:48:26.947581+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Keros Therapeutics reports Q2 2024 net loss of $45.3M; cash runway into 2027

## Summary
- Net loss of $45.3M in Q2 2024, up from $37.5M in Q2 2023 due to increased R&D spend.
- R&D expenses $40.5M (Q2 2024) vs $32.5M (Q2 2023); G&A $10.0M vs $8.8M.
- Cash and equivalents $405.9M as of June 30, 2024, expected to fund operations into 2027.
- Elritercept (KER-050) positive regulatory/data updates; cibotercept (KER-012) Phase 2 PAH enrollment to complete Q4 2024.

## SEC filing metadata
- accession: 0001664710-24-000067
- form_type: 8-K
- ticker: KROS
- cik: 0001664710
- company_name: Keros Therapeutics, Inc.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1664710/000166471024000067/0001664710-24-000067-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1664710/000166471024000067/kros-20240807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001664710-24-000067
- JSON: https://secwatch.observer/filing/0001664710-24-000067.json
- Plain text: https://secwatch.observer/filing/0001664710-24-000067.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.